Viatris VTRS NASDAQ · Healthcare · United States
$20.45 -1.40% -$0.29
Summary
35 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 14 USD is left as free cash.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- The share price is above the Bulios Fair Price.
- Revenue fell by 4.2% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.7% a year over 5 years. Over the last 3 years it fell by 4.2% a year. For the next fiscal year analysts expect revenue to grow by 3.5%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $607.8M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 2.35%
You receive $0.48 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 5
- Hold 7
- Sell 1
Today's price within the analysts' price targets
The average target of $22.17 is 8.4% above today's price. 38% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Brands 64%
- Generics 36%
By region
- Developed Markets Segment 60%
- Greater China Segment 16%
- Emerging Markets Segment 16%
- Japan, Australia and New Zealand Segment 8.4%
Brands brings in 64% of revenue.
Segments in detail